#1Ocuphire Restore Vision & Clarity MIRA-2 Phase 3 Trial Results Conference Call March 15, 2021#22 Disclosures and Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire Pharma, Inc.'s ("Ocuphire" or the "Company") product candidates and potential. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) timing or ability for the company to achieve its targeted milestones; (ii) the success and timing of regulatory submissions and pre-clinical and clinical trials; (iii) regulatory requirements or developments; (iv) changes to clinical trial designs and regulatory pathways; (v) changes in capital resource requirements; (vi) risks related to the inability of the Company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vii) legislative, regulatory, political and economic developments, and (viii) the effects of COVID-19 on clinical programs and business operations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by the Company from time to time with the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. The Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information contained in or incorporated by reference into this presentation. Nothing contained in or incorporated by reference into this presentation is, or shall be relied upon as, a promise or representation by the Company as to the past or future. The Company assumes no responsibility for the accuracy or completeness of any such information. This presentation may not be reproduced or provided to any other person (other than your advisor) without our prior written consent. By accepting delivery of this presentation, you agree to the foregoing and agree to return this presentation and any documents related thereto and any copies thereof to us or to destroy the same if you do not make an investment in any securities. The information contain within this presentation shall not, except as hereinafter provided, without the prior written consent of the Company, be disclosed by you or your representatives in any manner whatsoever, in whole or in part, and shall not be used by you or your representatives other than for the purpose of evaluating the transaction described herein. By accepting delivery of this presentation you further acknowledge and agree aware of the restrictions imposed by the United States securities laws on the purchase or sale of securities by any person who has received material, nonpublic information from the issuer of the securities or any affiliate thereof and on the communication of such information to any other person when it is reasonably foreseeable that such other person is likely to purchase or sell such securities in reliance on such information for so long as the information remains material and non- public. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. 7 November 6, 2020 NASDAQ CONGRATULATES OCUPHIRE ON RECENT LISTING AND CAPITAL RAISE OCUPHIRE PHARMA Ocuphire OCUP Nasdaq Listed Nasdaq LEADE ****#33 Agenda and Participants. First Phase 3 Trial Topline Readout as Planned in 1Q21 ● ● ● ● Topline MIRA-2 Phase 3 Clinical Trial Results for Nyxol in Reversal of Mydriasis Reversal of Mydriasis Market Opportunity Future Milestones Q&A Participants Mina Sooch, MBA, President and CEO Jay Pepose, MD, Medical Advisory Board Susan Benton, MBA, Corporate Board Member Mitch Brigell, PhD, Head of Clinical Development Charlie Hoffmann, MBA, VP of Corporate Development and Operations Amy Rabourn, MBA, VP of Finance Ocuphire PHARMA#44 Ocuphire Pipeline & Upcoming Milestones Multiple Phase 3 & Phase 2 Clinical Data Readouts Anticipated Over the Next Year Ocuphire-Focused Development Partnering- Focused Development Product Candidate 0.75% NyxolⓇ Eye Drop 0.75% NyxolⓇ Eye Drop 0.75% Nyxol® + Low-Dose 0.4% Pilocarpine Eye Drops APX3330 Oral Pill APX2009 Intravitreal Combo (0.75% NyxolⓇ + Latanoprost) Eye Drops Indication Dim Light or Night Vision Disturbances (NVD) Reversal of Mydriasis (RM) Presbyopia (P) Diabetic Retinopathy (DR)/ Macular Edema (DME) DME, Wet Age-Related Macular Degeneration (wAMD) Glaucoma (16 to 24 mmHg) Pre-clinical Development Stage Phase 1 Phase 2 Phase 3 Enrollment Complete/Data Readout Anticipated Milestones Initiated Phase 3 LYNX-1 trial 4Q2020; Data expected in 3Q21 (n=160) Initiated Phase 3 MIRA-2 trial 4Q2020; Topline data reported in 1Q21 (n=185) Initiated Phase 2 VEGA-1 trial 1Q2021; Data expected in 2Q21 (n=152) Initiate Phase 2 ZETA-1 trial 1Q2021; Data expected by early 2022 (n=100) Next steps: IND enabling studies (with partner funding) Next steps: 2nd line add-on Phase 2 trial (with partner funding) Note: 0.75% Nyxol (Phentolamine Ophthalmic Solution) is the same as 1% Nyxol (Phentolamine Mesylate Ophthalmic Solution) Ocuphire PHARMA#5LO 5 NyxolⓇ NVD RM P Night Vision Disturbances Reversal of Mydriasis Presbyopia H N Ocuphire N PHARMA Phentolamine Mesylate OH • CH3SO3H#6CO 6 Ocuphire PHARMA Topline MIRA-2 Phase 3 Results Randomized, Parallel Arm, Double-Masked, Placebo- Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy Subjects#7RM 7 Objectives and Key Eligibility Criteria MIRA-2 (OPI-NYX-RM-301) Phase 3 Trial Evaluating Reversal of Mydriasis with Nyxol or Placebo Key Objectives PRIMARY To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced across multiple mydriatic agents KEY SECONDARY • To evaluate the safety of Nyxol ● mydriasis To evaluate multiple secondary endpoints for the reversal of pharmacologically- induced mydriasis across mydriatic agents and iris color Clinical trial NCT #04620213 ● Key Eligibility Criteria Inclusion Healthy ≥ 12 years of age • Exclusion - Clinically significant ocular disease Ocular trauma, ocular surgery or non-refractive laser treatment within the 6 months prior to screening. - Use of any topical prescription or over-the- counter (OTC) ophthalmic medications of any kind within 7 days of screening Recent or current evidence of ocular infection or inflammation in either eye History of any traumatic (surgical or nonsurgical) or non-traumatic condition affecting the pupil or iris Ocuphire PHARMA#8RM 8 RM MIRA-2 Phase 3 Registration Design Randomized, Double-Masked, Placebo-Controlled, Parallel, One-Day Trial MIRA-2 12 US sites 168 target healthy subjects Eligibility Screening 1:1 Randomization 0.75% Nyxol Mydriatic Agent A, B, or C Mydriasis Time 1 Hour Placebo Mydriatic Agent A, B, or C Nyxol drop(s) (2 drops study eye, 1 drop fellow eye) Treatment Time 0 (Max Dilation) Placebo drop(s) (2 drops study eye, 1 drop fellow eye) Started and Completed Enrollment in 4Q20 - 185 Subjects Topline Results Expected in 1Q21 – Reported on 3/15/21 Endpoints Primary: % of subjects (study eye) returning to baseline (within 0.2 mm) pupil diameter (PD) at 90 min Secondary: • % of subjects returning to baseline at 30min, 1h, 2h, 3h, 4h, 6h, 24h (overall, by mydriatic agent, by iris color) ● ● ● Mean change in pupil diameter from mydriatic max at all timepoints (overall, by mydriatic agent, by iris color) Accommodation (Tropicamide/Paremyd) Safety and tolerability (redness) Mydriatic Agents 3:1:1 - 2.5% phenylephrine (alpha 1 agonist), 1% tropicamide (cholinergic blocker), Paremyd® (combination) Ocuphire PHARMA#9RM 9 Demographics (mITT Population) Treatment and Placebo Arms Were Balanced in this Phase 3 Registration Trial Demographics Age (years): Median (Range) Sex: Male n (%) Female n (%) Race: White n (%) African American n (%) Asian n (%) Other^ n (%) ^includes American Indian or Alaska Native; Native Hawaiian or Other Pacific Islander Nyxol n=94 Source: MIRA-2 TLR table #14.1.2.3 modified Intent To Treat (mITT) 31 (12-70) 36 (38%) 58 (62%) 70 (75%) 17 (18%) 6 (6%) 2 (2%) Placebo n=91 30 (13-73) 36 (40%) 55 (60%) 74 (81%) 16 (18%) 3 (3%) 1 (1%) Total n=185 46 (51%) 45 (50%) 31 (12-73) 72 (39%) 113 (61%) 95 (51%) Dark Iris Color: n (%) 49 (52%) 45 (48%) 90 (49%) Light Iris Color: n (%) Note: 14 pediatric subjects 12-17years old were enrolled in the trial; Race is more than 100% given subjects could check more than one category. 144 (78%) 33 (18%) 9 (5%) 3 (2%) Ocuphire PHARMA#10RM 10 Baseline Characteristics Study Eye (mITT Population) Treatment and Placebo Arms Were Balanced Across These Ocular Measurements Baseline Characteristic Baseline Pupil Diameter Mean (mm) Max Dilated Pupil Diameter Mean (mm) Accommodation Median (diopters) BCDVA letters 55 letters = 20/20 DCNVA letters 70 letters = 20/20 IOP (mmHg) Source: MIRA-2 TLR table #14.1.2.3 (mITT) Nyxol n=94 5.09 7.21 7.28 57 58 15.3 Placebo n=91 5.18 7.20 7.41 59 61 15.1 Total n=185 5.13 7.20 7.41 58 59 15.2 Ocuphire PHARMA#11RM 11 Primary Endpoint: % of Subjects Study Eye Returning to Baseline PD at 90 Min Nyxol Met the Primary Endpoint at 90 Min; Additionally at 60 Min and All Subsequent Timepoints Percent of Subjects (%) 100% 80% 60% 40% 20% 0% 3% Placebo n=91 1% 0.5 2% MIRA-2 Phase 3 Trial Study Eye (mITT Population) Percent of Subjects Returning to ≤ 0.2 mm of Baseline Nyxol n=94 p<0.0001 28% 1 p<0.0001 49% 7% p<0.0001 59% 11% p<0.0001 80% 2 18% 1.5 Time Post-Treatment with Nyxol/Placebo (Hours) 3 Source: MIRA-2 TLR table #14.2.1.1 (mITT). Data include all three mydriatics (Phenylephrine, Tropicamide, Paremyd) p<0.0001 82% 30% 4 p<0.0001 90% 45% 6 Ocuphire PHARMA#12RM 12 Percent of Subjects (%) Secondary Endpoint: % of Subjects Returning to Baseline PD by Mydriatic Agent Subjects Dilated with Phenylephrine had a Faster Response to Nyxol than Tropicamide/Paremyd 100% 80% 60% 40% 20% 0% Placebo n=55 Nyxol n=56 Placebo n=55 Nyxol n=56 0.5 6% 2% MIRA-2 Phase 3 Trial Study Eye (mITT Population) Percent of Subjects Returning to ≤ 0.2 mm of Baseline by Mydriatic Agent Phenylephrine 1 4% 46% p<0.0001 p<0.0001 p<0.0001 JUI 1.5 11% 79% 2 18% 82% p<0.0001 p<0.0001 p<0.05 Source: MIRA-2 TLR table # 14.2.1.4 (mITT) 3 29% 86% 4 44% 84% Time Post-Treatment with Nyxol/Placebo (Hours) 6 56% 86% Percent of Subjects (%) 100% 80% 60% 40% 20% 0% Placebo (n=36) Nyxol (n=38) Tropicamide or Paremyd Placebo (n=36) Nyxol (n=38) 0.5 0% 0% 1 0% 0% 1.5 0% 5% p<0.05 2 0% 24% p<0.0001 p<0.001 11 3 0% 71% 4 8% 79% Time Post-Treatment with Nyxol/Placebo (Hours) p<0.0001 6 28% 97% Ocuphire PHARMA#13RM Percent of Subjects (%) Secondary Endpoint: % of Subjects Returning to Baseline PD by Iris Color Evidence of Efficacy in Subjects with Both Light and Dark Irides, with a More Vigorous Response in Light Irides 13 100% 80% 60% 40% 20% 0% Placebo n=45 Nyxol n=45 Placebo n=45 0.5 0% 0% p<0.01 MIRA-2 Phase 3 Trial Study Eye (mITT Population) Percent of Subjects Returning to ≤ 0.2 mm of Baseline by Iris Color Light Irides Dark Irides 1 0% 31% Nyxol n=45 p<0.0001 p<0.0001 p<0.0001 p<0.0001 p<0.0001 H 1.5 2 4 2% 7% 3 13% 89% 24% 96% 56% 71% Time Post-Treatment with Nyxol/Placebo (Hours) 6 49% 93% 100% 80% 60% 40% 20% 0% Placebo n=46 ■Nyxol n=49 Placebo n=46 0.5 7% 2% Source: MIRA-2 TLR table #14.2.1.6 (mITT). Data includes all three mydriatics (Phenylephrine, Tropicamide, Paremyd) p<0.01 Nyxol n=49 1 4% 25% p<0.001 11 2 3 15% 22% 47% 71% Time Post-Treatment with Nyxol/Placebo (Hours) p<0.001 1.5 11% 43% p<0.0001 p<0.001 4 35% 69% p<0.0001 6 41% 88% Ocuphire PHARMA#14RM 14 Secondary Endpoint: % of Subjects Non-Study Eye Returning to Baseline PD A Similar Significant Effect was Obtained with a Single Drop of Nyxol in the Non-Study Eye Percent of Subjects (%) 100% 80% 60% 40% 20% 0% Placebo (n=91) 2% 2% 0.5 Non-Study Eye (mITT Population) Percent of Subjects Returning to ≤ 0.2 mm of Baseline Nyxol (n=94) p<0.001 6% 1 MIRA-2 Phase 3 Trial 25% p<0.0001 49% 6% 1.5 p<0.0001 51% 10% 2 p<0.0001 68% 14% Source: MIRA-2 TLR table 14.2.1.2 (mITT). Data includes all three mydriatics (Phenylephrine, Tropicamide, Paremyd) 3 Time Post-Treatment with Nyxol/Placebo (Hours) p<0.0001 76% 24% 4 p<0.0001 86% 45% 6 Ocuphire PHARMA#15RM 15 Secondary Endpoint: Mean Pupil Diameter Over Time Nyxol Treatment Significantly Reduced PD Starting at 1 Hour Post-Dose through 6 Hours Mean Pupil Diameter (mm) 9 00 CO 3 Mydriatic -1 I ± Max pupil dilation, Treatment 0 F 0.5 p<0.0001 1 MIRA-2 Phase 3 Trial Study Eye, mITT Population p<0.0001 T p<0.0001 I p<0.0001 -Nyxol n=94 3 I p<0.0001 1.5 2 4 Time Post-Treatment with Nyxol/Placebo (Hours) Placebo n=91 Source: MIRA-2 TLR table # 14.2.2.1 (mITT). Standard Error bars are shown. Data includes all three mydriatics (Phenylephrine, Tropicamide, Paremyd) H p<0.0001 6 Ocuphire PHARMA#16RM 16 Secondary Endpoint: Mean Pupil Diameter Over Time by Mydriatic Agent Nyxol Reduced Pupil Diameter With All Mydriatic Agents; More Rapidly with Phenylephrine as Expected Pupil Diameter (mm) 9 8 LO 4 3 Mydriatic L -1 1 Max pupil dilation, Treatment p<0.0001 T Phenylephrine p<0.0001 -Nyxol n=56 T p<0.0001 I I p<0.0001 p<0.0001 MIRA-2 Phase 3 Trial Study Eye, mITT Population Placebo n=55 4 0 0.5 1 1.5 2 3 Time Post-Treatment with Nyxol/Placebo (Hours) p<0.0001 H Source: MIRA-2 TLR table #14.2.2.3 (mITT). Standard Error bars are shown. 6 Pupil Diameter (mm) 9 8 4 3 ± Max pupil dilation, Treatment Mydriatic Tropicamide or Paremyd p<0.0001 p<0.0001 X p<0.0001 -Nyxol n=38 -1 0 0.5 1 1.5 2 T p<0.0001 p<0.0001 Placebo n=36 3 4 Time Post-Treatment with Nyxol/Placebo (Hours) p<0.0001 +4 Ocuphire PHARMA#17RM Pupil Diameter (mm) 17 9 8 LO 4 3 Secondary Endpoint: Mean Pupil Diameter Over Time by Eye Color Nyxol Reduced Pupil Diameter More Rapidly in Both and Light Dark Irides p<0.0001 I Max pupil dilation, Treatment Mydriatic -1 0 0.5 TH p<0.0001 Light Irides T I p<0.0001 -Nyxol (n=45) I TH p<0.0001 +4 p<0.0001 MIRA-2 Phase 3 Trial Study Eye, mITT Population Placebo (n=45) 1 1.5 2 3 4 Time Post-Treatment with Nyxol/Placebo (Hours) I p<0.0001 6 Pupil Diameter (mm) 9 8 4 3 Max pupil dilation, Treatment Mydriatic -1 0 +4 p<0.0001 Dark Irides p<0.0001 p<0.0001 -Nyxol (n=49) Source MIRA-2 TLR table # 14.2.1.5. Standard Error bars are shown. Data includes all three mydriatics (Phenylephrine, Tropicamide, Paremyd) T p<0.0001 I Placebo (n=46) I p<0.0001 0.5 1 1.5 2 3 4 Time Post-Treatment with Nyxol/Placebo (Hours) HA I p<0.0001 6 Ocuphire PHARMA#18RM 18 • There were no deaths, serious AEs, or withdrawals due to AEs Only AEs, occurring in ≥ 5% of subjects treated with Nyxol, were instillation site discomfort (38% Nyxol vs. 9% placebo) and conjunctival hyperemia (13% Nyxol vs. 0% placebo) ● Secondary Endpoint: Safety Findings Nyxol was Well Tolerated with a Favorable Safety Profile ● 94% of the AEs in the Nyxol group were mild Conjunctival hyperemia was observed to be mild and transient From a baseline mean of 0.7, the mean hyperemia score increased by approximately 1.0 unit (on a 4-point scale) at 60 minutes post-dose and decreased steadily thereafter ● None (0) Mild (+1) 6 Moderate (+2) Visual acuity was not adversely affected by Nyxol Severe (+3) Source MIRA-2 Safety Population TLR table 14.3.1.1.; MIRA-2 table 14.3.1.2.2 System Organ Class; MIRA-2 table 14.3.3.2 Hyperemia Score by Time Point Ocuphire PHARMA#19RM 19 Summary of Positive MIRA-2 Phase 3 Results for Nyxol Eye Drops Sustained Efficacy with a Favorable Safety Profile in Reversing Mydriasis with Nyxol ● ● ● ● Met primary endpoint at 90 minutes with high statistical significance with 2 drops of Nyxol Met all key secondary endpoints with high statistical significance 1. Efficacy for all 3 mydriatic agents - phenylephrine, tropicamide, and ParemydⓇ 2. Efficacy in both light and dark iris colors. 3. Efficacy with only one Nyxol drop in non-study eye Favorable safety profile Mild, transient conjunctival hyperemia reported in the first hour and declined steadily thereafter No serious AEs, no drop-outs from AEs, no systemic AEs were observed in ≥ 5% of subjects Validates Nyxol mechanism of action, therapeutic effect, and safety profile in the other two indications of presbyopia and night vision disturbances - MIRA-2 Topline Reports (TLR) Ocuphire PHARMA#20RM 20 Next Steps For Nyxol RM Indication for NDA NDA Submission Expected Early 2023 ● Perform a second Phase 3 RM registration trial (MIRA-3) Planned 330 subjects randomized 2:1 to Nyxol or Placebo In addition to confirming efficacy, this trial will satisfy the regulatory requirement for number of subjects (300 or more) exposed for approval for acute use (24 hours) Limited pharmacokinetic sampling will be obtained in a small subset of subjects ● ● Results anticipated 1Q2022 Perform a small (20-30 subjects) pediatric RM trial (age 3 - 17 years) to satisfy pediatric research plan regulatory requirement • Manufacture and complete one-year stability on three registration batches for Nyxol single unit dose Blow-Fill-Seal vials Proposed Indication The treatment of pharmacologically induced mydriasis produced by adrenergic (e.g. phenylephrine) or parasympatholytic (e.g. tropicamide) agents, or a combination thereof. Nyxol End of Phase 2 FDA Meeting minutes Ocuphire PHARMA#2121 Ocuphire Reversal of Mydriasis Market Opportunity#22RM 22 Nyxol Product Candidate Profile Novel Alpha 1/2 Blocker Eye Drop for Refractive Indications (505(b)(2) Pathway) Nyxol: Phentolamine 0.75% Ophthalmic Solution Preservative Free, EDTA Free, and Stable Efficacy Data Safety Data Improving Vision ↓ Pupil Size (moderate miotic) ↑ Contrast Sensitivity (night) ↑ Near Visual Acuity (light/dark) ↑ Distance Visual Acuity No Systemic Effects No Changes in Blood Pressure No Changes in Heart Rate Tolerated Topical Effects Mild / Transient / Reversible Eye Redness IOP Unchanged or Decreased ↓ Intraocular Pressure (IOP) at Normal Baseline Chronic daily dosing of Nyxol at bedtime demonstrated no significant daytime redness and durability of effects for more than 24 hours Ocuphire PHARMA#23RM 23 Reversal of Mydriasis (RM) - Acute Treatment Annual Exams and Specialty Visits Involve Dilation to Monitor Eye Health The Problem • At many annual eye exams and specialty visits, pupils are pharmacologically dilated, impairing vision for 6-24 hours Dilated eyes: heightened sensitivity to light - inability to focus reading, working, and driving are difficult halos and glare - ee I have to stay indoors. They say it only lasts a few hours, but it lasts all day, and it is very annoying. 99 RM Patient, Aged 51 Source: GlobalData Market Research Report, 2020 No Current Commercially Available Treatments ~100M eye exams / year in US Ocuphire PHARMA#24RM 24 Reversal of Mydriasis (RM) - Acute Treatment Single Use Indication Leveraging a Precedent Approval Pathway ● ● ● ● Nyxol's Potential Differentiated Solution Regulatory Precedent with Rev-Eyes (an alpha 1 blocker), approved by the FDA in 1990 but shortly thereafter discontinued (not for safety or efficacy reasons) Clinical Effect to potentially reduce pupil size and counteract the effect of mydriatic drugs (alpha agonists and cholinergic blockers) used to dilate the pupil Convenient eye drop given at the office that may allow vision to return to normal sooner Tolerable with a minimal side effect profile (unlike cholinergic agonists such as pilocarpine) Source: GlobalData Market Research Report, 2020 Before After Seeking Treatment Findings Patients likely to request reversal of dilation Eye care providers likely to use reversal drops 45% 40% Ocuphire PHARMA#25RM 25 Nyxol Comparison to Rev-Eyes Nyxol has a Distinct Commercial Advantage to Rev-Eyes Tolerability Comfort Side effects Commercial Product Presentation No. of drops instilled ● ● Nyxol Mild hyperemia Mild discomfort (38%), erythema (4%), or instillation pain (3%) None reported Stable Preservative-free Sterile Single-unit dose packaging Normo-osmolar solution 1-2 drops/eye ● ● ● ● ● Rev-Eyes Severe hyperemia (80%) Burning/Stinging (50%) 40% (ptosis - droopy eyelids) Requires aseptic technique for reconstitution and mixing at physician office Stable for 21 days after product is reconstituted Contains preservative Hyperosmolar solution 4 drops/eye (2 drops, followed 5 minutes later by 2 additional drops) Source: Rev-Eyes (Dapiprazole HCL) Eyedrops 0.5% Summary Basis of Approval None (0) Normal Appears white with a small number of conjunctival blood vessel easily observed Mild (+1) Prominent, pinkish- red color of both the bulbar and palpebral conjunctiva Nyxol O Moderate (+2) Bright, scarlet red color of the bulbar and palpebral conjunctiva Severe (+3) Beefy red with petechiae, dark red bulbar and palpebral conjunctiva with evidence of subconjunctival hemorrhage Rev-Eyes Ocuphire PHARMA#26RM 26 ● ● ● ● Summary of RM Market Opportunity A Substantial Revenue Opportunity for Nyxol in Reversal of Mydriasis ~100M comprehensive and specialty eye exams in US per year No current commercially available treatment for reversing dilation Optomap ultra-wide field camera used for a retinal evaluation without the need for dilation; -$40-$65 cost to patient¹ Findings from recent US market research²: Over 65% patients report moderate to severe negative impact of dilated exams Cash pay price range surveyed $5-$20 per patient treatment 45% patients said they would likely request a dilation reversal drop Estimated US Market Opportunity- $325M- $1B+ - - Eye exam market posted a 3.3% growth to $6.39B³ Given the efficacy of Nyxol to reverse dilation regardless of eye color, there are additional markets outside of the US for potential commercialization 1. Corcoran Consulting Group FAQ for Optomap imaging 01/2021 2. GlobalData market research report 3. Vision Care Market Grows 2.4 Percent in 12-Months Ending September 2019. Vision Monday, January 20, 2020. Ocuphire PHARMA#2727 Future Milestones Ocuphire PHARMA#2828 2021 to 2022 Ocuphire Cadence of Milestones Multiple Data Catalysts on Path to NDA(s) 2018/2019 ✓ NVD Podium Presentation at AAO 2018 Initiate/Report Phase 2b Data for ORION-1 Initiate/Report Phase 2b Data for MIRA-1 Expand Patent Estate 1H 2020 Completion of APX3330 License ARVO 2020 Presentation for MIRA-1 ARVO 2020 Presentation for ORION-1 FDA EOP2 Meeting May 2020 2H 2020 Announced Ocuphire Reverse Merger and PIPE Financing (Co- Led by Cantor and Canaccord) ✓ Completion of Transaction (Nasdaq: OCUP) Initiate Phase 3 RM Trial ✓ Initiate Phase 3 NVD Trial ✓ Complete Nyxol Market Research ✓ Journal Publications 1H 2021 Enrollment of Phase 3 RM Trial Initiate Phase 2 Presbyopia Trial Report Positive Phase 3 Data for RM Initiate Phase 2 DR/DME Trial Enrollment of Phase 2 Presbyopia Trial Report Phase 2 Data for Presbyopia New Patent Claims 2H 2021 O Enrollment of Phase 3 NVD Trial Report Phase 3 Data for NVD O Enrollment of Phase 2 DR/DME Trial Industry Conferences & Publications Complete 6-month Rabbit Tox Study Registration Batches for Nyxol Blow-Fill- Seal Eye Drops Initiate 2nd P3 RM & Ped RM trial for NDA Ongoing partnering discussions with leading ophthalmic companies (including European and Asian players) 2022 Report 2nd Ph3 RM Report Phase 2 Data for DR/DME Initiate 2 Phase 3 Presbyopia Trials Initiate 2nd P3 NVD Initiate Chronic Ph3 NVD Safety Trial Report 2nd P3 NVD Report Phase 3 Data for Presbyopia Initiate Phase 3 DR/DME Trial(s) Registration Batches for APX3330 tablets Nyxol NDA filing for RM and/or NVD in early 2023 Ocuphire PHARMA#29Ocuphire Restore Vision & Clarity Q&A www.ocuphire.com [email protected]